• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

经癌症特异性 TCR 基因转导的 gammadelta T 细胞中快速的alphabeta TCR 介导的反应。

Rapid alphabeta TCR-mediated responses in gammadelta T cells transduced with cancer-specific TCR genes.

机构信息

Department of Immunno-Gene Therapy, Mie University Graduate School of Medicine, Mie, Japan.

出版信息

Gene Ther. 2009 May;16(5):620-8. doi: 10.1038/gt.2009.6. Epub 2009 Feb 26.

DOI:10.1038/gt.2009.6
PMID:19242528
Abstract

Adoptive T-cell transfer of in vitro cultured T cells derived from cancer patients with naturally developed immune responses has met with some success as an immunotherapeutic approach, although only a limited number of patients showed spontaneous immune responses. To find alternative ways, such as cancer-specific T-cell receptor (TCR) gene transfer, in preparation for sufficient numbers of antigen-specific T cells is an important issue in the field of adoptive T-cell therapy. Given the inherent disadvantage of alphabeta TCR transfer to other alphabeta T cells, namely the possible formation of mixed TCR heterodimers with endogenous alpha or beta TCR, we employed gammadelta T cells as a target for retroviral transfer of cancer-specific TCR and examined whether gammadelta T cells were useful as an alternative population for TCR transfer. Although retroviral transduction to gammadelta T cells with TCR alphabeta genes alone, isolated from a MAGE-A4(143-151)-specific alphabeta CD8(+) cytotoxic T lymphocyte (CTL) clone, did not provide sufficient affinity to recognize major histocompatibility (MHC)-peptide complexes due to the lack of CD8 co-receptor, gammadelta T cells co-transduced with TCR alphabeta and CD8 alphabeta genes acquired cytotoxicity against tumor cells and produced cytokines in both alphabeta- and gammadelta-TCR-dependent manners. Furthermore, alphabeta TCR and CD8-transduced gammadelta T cells, stimulated either through alphabeta TCR or gammadelta TCR, rapidly responded to target cells compared with conventional alphabeta T cells, reminiscent of gammadelta T cells. We propose alphabeta TCR-transduced gammadelta T cells as an alternative strategy for adoptive T-cell transfer.

摘要

采用体外培养的癌症患者自然产生免疫反应的 T 细胞进行过继性 T 细胞转移作为一种免疫治疗方法已经取得了一定的成功,尽管只有少数患者表现出自发的免疫反应。为了寻找替代方法,例如癌症特异性 T 细胞受体(TCR)基因转移,以便为足够数量的抗原特异性 T 细胞做准备,这是过继性 T 细胞治疗领域的一个重要问题。鉴于将 αβTCR 转移到其他 αβT 细胞存在固有劣势,即可能与内源性 α 或 βTCR 形成混合 TCR 异二聚体,我们利用 γδT 细胞作为癌症特异性 TCR 逆转录病毒转移的靶标,并研究了 γδT 细胞是否可用作 TCR 转移的替代群体。尽管单独用从 MAGE-A4(143-151)-特异性 αβCD8(+)细胞毒性 T 淋巴细胞(CTL)克隆中分离的 TCR αβ基因对 γδT 细胞进行逆转录病毒转导,由于缺乏 CD8 共受体,无法提供足够的亲和力来识别主要组织相容性(MHC)-肽复合物,但 γδT 细胞共转导 TCR αβ和 CD8 αβ基因后,能够获得针对肿瘤细胞的细胞毒性,并以 αβ-TCR 和 γδ-TCR 依赖的方式产生细胞因子。此外,与传统的 αβT 细胞相比,刺激通过 αβTCR 或 γδTCR 刺激的 αβTCR 和 CD8 转导的 γδT 细胞能够快速响应靶细胞,这让人联想到 γδT 细胞。我们提出 αβTCR 转导的 γδT 细胞作为过继性 T 细胞转移的替代策略。

相似文献

1
Rapid alphabeta TCR-mediated responses in gammadelta T cells transduced with cancer-specific TCR genes.经癌症特异性 TCR 基因转导的 gammadelta T 细胞中快速的alphabeta TCR 介导的反应。
Gene Ther. 2009 May;16(5):620-8. doi: 10.1038/gt.2009.6. Epub 2009 Feb 26.
2
Long-term phenotypic, functional and genetic stability of cancer-specific T-cell receptor (TCR) alphabeta genes transduced to CD8+ T cells.转导至CD8+ T细胞的癌症特异性T细胞受体(TCR)αβ基因的长期表型、功能和遗传稳定性
Gene Ther. 2008 May;15(9):695-9. doi: 10.1038/sj.gt.3303099. Epub 2008 Feb 21.
3
Redirecting human CD4+ T lymphocytes to the MHC class I-restricted melanoma antigen MAGE-A1 by TCR alphabeta gene transfer requires CD8alpha.通过TCRαβ基因转移将人CD4 + T淋巴细胞重定向至MHC I类限制性黑色素瘤抗原MAGE-A1需要CD8α。
Gene Ther. 2005 Jan;12(2):140-6. doi: 10.1038/sj.gt.3302388.
4
Reconstitution of anti-HIV effector functions of primary human CD8 T lymphocytes by transfer of HIV-specific alphabeta TCR genes.通过转移HIV特异性αβTCR基因重建原代人CD8 T淋巴细胞的抗HIV效应功能。
Eur J Immunol. 2004 Dec;34(12):3379-88. doi: 10.1002/eji.200425568.
5
Alphabeta T-cell receptor engineered gammadelta T cells mediate effective antileukemic reactivity.αβ T细胞受体工程改造的γδ T细胞介导有效的抗白血病反应性。
Cancer Res. 2006 Mar 15;66(6):3331-7. doi: 10.1158/0008-5472.CAN-05-4190.
6
Expression of costimulatory molecules (CD80, CD86, CD28, CD152), accessory molecules (TCR alphabeta, TCR gammadelta) and T cell lineage molecules (CD4+, CD8+) in PBMC of leprosy patients using Mycobacterium leprae antigen (MLCWA) with murabutide and T cell peptide of Trat protein.利用麻风分枝杆菌抗原(MLCWA)、murabutide及Trat蛋白的T细胞肽,检测麻风患者外周血单个核细胞中共刺激分子(CD80、CD86、CD28、CD152)、辅助分子(TCRαβ、TCRγδ)及T细胞谱系分子(CD4 +、CD8 +)的表达情况。
Int Immunopharmacol. 2004 Jan;4(1):1-14. doi: 10.1016/j.intimp.2003.09.001.
7
Human gammadelta T cells as mediators of chimaeric-receptor redirected anti-tumour immunity.人类γδ T细胞作为嵌合受体重定向抗肿瘤免疫的介质。
Br J Haematol. 2004 Aug;126(4):583-92. doi: 10.1111/j.1365-2141.2004.05077.x.
8
Simultaneous generation of CD8+ and CD4+ melanoma-reactive T cells by retroviral-mediated transfer of a single T-cell receptor.通过逆转录病毒介导的单一T细胞受体转移同时产生CD8 +和CD4 +黑色素瘤反应性T细胞。
Cancer Res. 2005 Feb 15;65(4):1570-6. doi: 10.1158/0008-5472.CAN-04-2076.
9
HLA class II restricted T-cell receptor gene transfer generates CD4+ T cells with helper activity as well as cytotoxic capacity.HLA II类分子限制性T细胞受体基因转移可产生具有辅助活性以及细胞毒性能力的CD4+ T细胞。
Gene Ther. 2005 Dec;12(23):1686-95. doi: 10.1038/sj.gt.3302586.
10
Loss of either CD4+ or CD8+ T cells does not affect the magnitude of protective immunity to an intracellular pathogen, Francisella tularensis strain LVS.CD4+或CD8+ T细胞的缺失并不影响对细胞内病原体土拉弗朗西斯菌LVS菌株的保护性免疫强度。
J Immunol. 1996 Dec 1;157(11):5042-8.

引用本文的文献

1
Engineering innate immune cells for cancer immunotherapy.通过工程改造天然免疫细胞进行癌症免疫治疗。
Nat Biotechnol. 2025 Apr;43(4):516-533. doi: 10.1038/s41587-025-02629-5. Epub 2025 Apr 14.
2
γδT cells, a key subset of T cell for cancer immunotherapy.γδT细胞,癌症免疫疗法中T细胞的一个关键亚群。
Front Immunol. 2025 Mar 28;16:1562188. doi: 10.3389/fimmu.2025.1562188. eCollection 2025.
3
TCR-T cell therapy for solid tumors: challenges and emerging solutions.用于实体瘤的TCR-T细胞疗法:挑战与新出现的解决方案
Front Pharmacol. 2025 Mar 10;16:1493346. doi: 10.3389/fphar.2025.1493346. eCollection 2025.
4
TCR-T cell therapy: current development approaches, preclinical evaluation, and perspectives on regulatory challenges.T 细胞受体嵌合型 T 细胞疗法:当前的开发方法、临床前评估,以及监管挑战的观点。
J Transl Med. 2024 Oct 4;22(1):897. doi: 10.1186/s12967-024-05703-9.
5
Advancements in γδT cell engineering: paving the way for enhanced cancer immunotherapy.γδT 细胞工程的进展:为增强癌症免疫疗法铺平道路。
Front Immunol. 2024 Mar 21;15:1360237. doi: 10.3389/fimmu.2024.1360237. eCollection 2024.
6
αβ-T cell receptor transduction gives superior mitochondrial function to γδ-T cells with promising persistence.αβ-T细胞受体转导赋予γδ-T细胞卓越的线粒体功能,并具有良好的持久性。
iScience. 2023 Aug 31;26(10):107802. doi: 10.1016/j.isci.2023.107802. eCollection 2023 Oct 20.
7
γδ T Cells for Leukemia Immunotherapy: New and Expanding Trends.γδ T 细胞用于白血病免疫治疗:新趋势与扩展趋势。
Front Immunol. 2021 Sep 22;12:729085. doi: 10.3389/fimmu.2021.729085. eCollection 2021.
8
Evolution of CD8 T Cell Receptor (TCR) Engineered Therapies for the Treatment of Cancer.嵌合抗原受体 T 细胞(CAR-T)疗法治疗癌症的研究进展。
Cells. 2021 Sep 10;10(9):2379. doi: 10.3390/cells10092379.
9
Off-the-Shelf Allogeneic T Cell Therapies for Cancer: Opportunities and Challenges Using Naturally Occurring "Universal" Donor T Cells.现货异体通用供体 T 细胞治疗癌症:利用天然存在的“通用”供体细胞的机遇与挑战。
Front Immunol. 2020 Nov 11;11:583716. doi: 10.3389/fimmu.2020.583716. eCollection 2020.
10
Development of adoptive immunotherapy with KK-LC-1-specific TCR-transduced γδT cells against lung cancer cells.采用 KK-LC-1 特异性 TCR 转导的 γδT 细胞进行过继免疫治疗肺癌。
Cancer Sci. 2020 Nov;111(11):4021-4030. doi: 10.1111/cas.14612. Epub 2020 Sep 16.